Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clonidine as a pharmacological challenge for CSF kinetics imaging
NCT04030572Phase 1Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- Dec 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Clonidine Lauriad in neurodegenerative disease and cancer, sponsored by Weill Cornell Medicine. Primary endpoint: Number of subjects experiencing adverse events related to drug-induced changes in hemodynamic function at Day 8. Started Dec 2019; status: terminated.
02
Drugs
Clonidine Lauriad
03
Conditions
neurodegenerative diseasecancer
Beyond the preview
Go deeper on NCT04030572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04030572.